Could a 4-Month TB cocktail replace the standard 6-Month cure?
NCT ID NCT05221502
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a new 4-month combination of three drugs (OPC-167832, delamanid, and bedaquiline) against the standard 6-month treatment for drug-susceptible pulmonary tuberculosis. 122 adults with newly diagnosed TB took part. The goal was to see if the shorter regimen is safe and can clear the infection faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OPC-167832 combined with delamanid and bedaquiline
What this could lead to
If successful, this could lead to a shorter, 4-month treatment for drug-susceptible tuberculosis, reducing the burden of long therapy.
What could go wrong
This is an early phase 2 trial with only 122 participants, so results may not confirm safety or effectiveness. The new combination may cause side effects or fail to cure TB as well as the standard 6-month regimen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Institute - Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa
-
Perinatal HIV Research Unit Tshepong Hospital Complex
Klerksdorp, 2574, South Africa
-
Setshaba Research Center
Pretoria, 0152, South Africa
-
TASK Applied Science, Brooklyn Chest Hospital Premises
Cape Town, 7100, South Africa
-
Themba Lethu Clinic Clinical HIV Research Unit (CHRU)
Johannesburg, 2092, South Africa
-
University of CapeTown Lung Center Institute
Cape Town, 7700, South Africa